Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute lymphoblastic leukemia.

Dieter Hoelzer1, Nicola Gökbuget, Oliver Ottmann

  • 1University Hospital, Medizinische Klinik III, Theodor Stern Kai 7, Frankfurt, Germany.

Hematology. American Society of Hematology. Education Program
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome.

Blood advances·2022
Same author

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.

Blood·2022
Same author

Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation.

Nature genetics·2022
Same author

Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia.

JAMA oncology·2022
Same author

Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care.

Children (Basel, Switzerland)·2021
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Recent advancements in acute lymphoblastic leukemia (ALL) include novel therapies like tyrosine kinase inhibitors and monoclonal antibodies. Minimal residual disease (MRD) monitoring is crucial for personalized treatment decisions in both adult and childhood ALL.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Acute lymphoblastic leukemia (ALL) remains a significant challenge in hematologic oncology.
  • Understanding treatment sequelae and long-term outcomes is vital for patient care.

Purpose of the Study:

  • To provide a comprehensive overview of recent developments in ALL diagnosis and treatment.
  • To review prognostic factors, risk stratification, and novel therapeutic strategies.
  • To discuss the role of minimal residual disease (MRD) in treatment decisions and outcomes.

Main Methods:

  • Review of current chemotherapy, tyrosine kinase inhibitors, and monoclonal antibodies.
  • Analysis of prognostic factors, risk stratification, and MRD detection methods (flow cytometry, PCR).

Related Experiment Videos

  • Examination of late treatment sequelae, second cancer risk, and stem cell transplantation outcomes.

    • Main Results:

    • Tyrosine kinase inhibitors and monoclonal antibodies represent new treatment options for ALL.
    • MRD detection is a valuable prognostic tool for guiding individualized treatment strategies.
    • Late sequelae and quality of life post-treatment and stem cell transplantation require careful management.

    Conclusions:

    • Personalized treatment approaches in ALL are increasingly guided by MRD.
    • Advances in therapy aim to improve outcomes while mitigating long-term toxicities.
    • Standardization of MRD detection and quality control are essential for reliable risk assessment.